Q2'25 report Q2 was a bit softer than expected with respect to both sales and profitability.
Redeye comments on CMS’s preliminary CPT-I codes payment rates.
On 15 July 2025, Føroya Banki raised its 2025 net profit guidance range to DKK 235-265m (previously ...
Redeye comments on Cantargia’s license deal with Otsaka Pharmaceutical, which is transformative for ...
Redeye provides an update following Episurf Medical’s Q2 2025 report, where net sales came in below ...
Redeye gives its initial take on BONESUPPORT’s Q2 report.
We expect double-digit earnings growth from Q4 Q2 was characterised by a stable organic performance ...
Better Norway offset by losses in Denmark Coor managed to turn both organic sales and EBITA growth p...
Redeye takes a more cautious approach toward the long-term prospects in Fiber Solutions, leading to ...
Top-line miss weighs on Q2 numbers FastPartner delivered Q2 results with rental income and net opera...
Redeye nudges down its estimates and valuation following Lifco’s Q2 2025 report.
Redeye provides an update following Iconovo’s Q2 report.
Redeye comments on Physitrack ahead of its Q2 results, due on 18 July (rescheduled from 31 July).
Redeye provides its initial take on Indutrade’s Q2 2025 report, which came in below our estimates.
Ahead of Atria's Q2 report, we maintain our estimates intact.
Q2 details Sales SEK 1,172m (0% vs ABG 1,170m, no cons).
Redeye sees a stable Q2 report from Addnode, with the relatively solid performance in PLM being the ...
Huge share price potential must be balanced against large risks in this exciting mine developer.
Plejd rapporterade för andra kvartalet 2025 en nettoomsättning om 210,7 MSEK (146,2), motsvarande en...
Earnings growth may not resume before Q4’25 DT cut Q2 guidance as security CT installations remaine...